[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 7 sources · 29 days · First seen · Last updated

Thyroid eye disease drug funding dispute in Spain

Overview

In Spain, the Spanish Association of Patients with Thyroid Eye Disease (EOT España) is demanding that the Ministry of Health and autonomous communities rectify a decision to deny funding for teprotumumab. The association argues that the refusal to fund the treatment on July 15 was an error that has negatively impacted patients' vision, social lives, and ability to work.

EOT España president Pilar Carnicero stated, “We are not asking for a new opportunity, we demand that an error that has already cost patients dearly be corrected.” The group is calling for action during the Interministerial Commission on Drug Prices meeting scheduled for September 23.

Entities

Ministry of Health · EOT España · European Medicines Agency · Pilar Carnicero · FDA

Timeline

  1. [BUSINESS] 5 sources
    Roche receives FDA approval for Enspryng to treat thyroid eye disease

    The FDA has approved Roche's Enspryng for treating thyroid eye disease in adults, expanding its use beyond neuromyelitis optica spectrum disorder.

  2. [HEALTH] 2 sources
    EOT España demands funding for authorized thyroid eye disease treatment

    EOT España is urging Spanish health authorities to fund teprotumumab, the only EMA-authorized treatment for thyroid eye disease, following a previous decision to deny coverage.

Sources

capital.es · finanzen.ch · isanidad.com · it-boltwise.de · polizeinews.ch · schweiznews.ch · t-online.de